Last reviewed · How we verify
BMS-986177
BMS-986177 is an anti-PD-1 monoclonal antibody.
BMS-986177 is an anti-PD-1 monoclonal antibody. Used for Non-small cell lung cancer, Melanoma.
At a glance
| Generic name | BMS-986177 |
|---|---|
| Also known as | Milvexian, JNJ-70033093 |
| Sponsor | Bristol-Myers Squibb |
| Drug class | anti-PD-1 monoclonal antibody |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BMS-986177 works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby enhancing T cell activation and proliferation. This leads to an increase in anti-tumor immune responses.
Approved indications
- Non-small cell lung cancer
- Melanoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (PHASE3)
- A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants (PHASE1)
- A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants (PHASE1)
- A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants (PHASE1)
- A Study of Milvexian in Healthy Adult Females (PHASE1)
- A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants (PHASE1)
- A Study of JNJ-70033093 and Digoxin in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |